



Investigating the B-Cell Receptor in bladder and kidney cancer to understand its role in anti-cancer immunity and its potential implications for cancer treatment and outcomes

Liliane Zoe Bader
M.Sc. Thesis
June 15th, 2025



AARHUS
UNIVERSITY
DEPARTMENT OF MOLECULAR BIOLOGY AND GENETICS



AARHUS
UNIVERSITY
HOSPITAL

Liliane Zoe Bader

Cancer Evolution & Immunology, Aarhus University Hospital

Investigating the B-Cell Receptor in bladder and kidney cancer to understand its role in anti-cancer immunity and its potential implications for cancer treatment and outcomes.

M.Sc. Thesis

June 2025

Aarhus University

Department of Molecular Biology and Genetics

Bioinformatics Research Centre

Universitetsbyen 81, building 1872, 3rd floor

DK-8000 Aarhus C, Denmark

<https://www.birc.au.dk>

This document was typeset in L^AT_EX.



ABSTRACT

B cells and their receptors (BCRs) play an increasingly recognized role in anti-tumor immunity, complementing the more extensively studied T-cell responses. This thesis investigates the BCR repertoires in bladder and kidney cancers, aiming to characterize their clonality, diversity and gene usage patterns, and to explore their associations with clinical outcomes. Utilizing high-throughput immune repertoire sequencing data from over 350 patient samples, including healthy controls, comprehensive bioinformatic and statistical analyses were conducted. Key findings include increased clonotype expansion and reduced diversity in cancer samples compared to healthy controls, along with distinct V(D)J gene usage patterns. Importantly, lower BCR diversity correlated with adverse clinical outcomes, such as reduced survival. UMAP-based dimensionality reduction and correlation heatmaps were applied to reveal associations between specific immunoglobulin gene segments and clinical variables, suggesting potential biomarkers for disease prognosis. These results emphasize the relevance of B cells in cancer immunology and support the integration of BCR repertoire analysis into future diagnostic and therapeutic strategies.



PREFACE

This thesis was written with the Cancer Evolution & Immunology Group at the Department of Molecular Medicine (MoMa), Aarhus University Hospital. I am very grateful to my supervisor, Professor Nicolai Juul Birkbak, head of the research group, for his guidance and support throughout the project. I would also like to thank the other members of the group, especially Postdoc Randi Istrup Juul, PhD student Asbjørn Kjær and Postdoc Ragnhild Liborius Laursen, for their valuable support.



Department of Molecular
Medicine
Aarhus University Hospital
Brendstrupgårdsvej 21A
8200 Aarhus N, Denmark
<https://www.moma.dk>

Thesis submitted:

June 15th, 2025

Author:

Liliane Zoe Bader
liba@clin.au.dk
au752655@uni.au.dk

Supervisor:

Nicolai Birkbak
Professor, PhD, MSc, Group leader
Cancer Evolution & Immunology
Department of Molecular Medicine
Aarhus University Hospital
nbirkbak@clin.au.dk

Pages: 60

Appendices: A-D

The contents of this M.Sc. thesis are freely accessible and distributed under the terms of the Creative Commons CC-BY license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. All analysis code used in this thesis is available at https://github.com/liliab98/bcr_analysis. Furthermore, none of the contents of this thesis includes plagiarism.

CONTENTS

1	Introduction	1
1.1	Motivation	1
1.2	Biological Background	1
1.2.1	B cells	1
1.2.2	B cells in and around Tumors	3
1.2.3	BCR structure	3
1.2.4	Generating BCR Diversity	3
1.3	State of the art	5
1.3.1	Initial BCR Repertoire Analysis	5
1.3.2	BCR Repertoires in Cancer Research	5
1.3.3	Research Gaps	6
2	Methods	7
2.1	Data Collection and Preprocessing	7
2.1.1	Clinical Context and Sample Collection	7
2.1.2	Sequencing Technology	7
2.1.3	Bioinformatic Preprocessing	8
2.1.4	Integration with Clinical Metadata	8
2.1.5	Limitations of the Data	8
2.2	Analysis	9
2.2.1	Clonotype Analysis	9
2.2.2	Diversity Analysis	11
2.2.3	Survival Analysis	13
2.2.4	Group Comparisons: Healthy vs. Cancer	14
2.2.5	Gene Usage Computation	15
2.2.6	Dimensionality Reduction with UMAP	16
2.2.7	Statistical Associations Between Gene Usage and Clinical Variables	17
3	Results	20
3.1	Clonotype Analysis	20
3.1.1	Unique Clonotypes and Read Depth	20
3.1.2	Clonotype Expansion	21
3.2	Diversity Analysis	23
3.2.1	Normalized Shannon Diversity Index and Gini Index	23

3.2.2	Diversity and Clinical Variables	24
3.2.3	Survival Analysis	27
3.3	Group Comparisons: Healthy vs. Cancer	29
3.3.1	Read Counts	29
3.3.2	Shannon Diversity	29
3.3.3	Top 10 Clone Fraction	30
3.3.4	Clonotypes Accounting for 50% of Reads	31
3.4	Gene Usage Analysis	31
3.4.1	Dimensionality Reduction with UMAP	31
3.4.2	Statistical Associations Between Gene Usage and Clinical Variables	32
4	Discussion	35
4.1	Interpretation of Results	35
4.2	Limitations and Analytical Considerations	41
4.3	Future Directions and Outlook	43
4.4	Conclusion	45
A	Appendix	51

LIST OF FIGURES

Figure 1	General overview of the development of a B cell and its functions. (Figure from [1])	2
Figure 2	General overview of the BCR structure and components. (Figure from [2])	4
Figure 3	General overview of the Bioinformatic Preprocessing	8
Figure 4	Unique clonotype count and read depth per chain for the bladder dataset.	20
Figure 5	Unique clonotype count and read depth per chain for the renal dataset.	21
Figure 6	Proportions of expanded and non-expanded clonotypes per chain in the bladder cohort.	22
Figure 7	Proportions of expanded and non-expanded clonotypes per chain in the renal cohort.	22
Figure 8	Diversity measures for the bladder cohort.	23
Figure 9	Diversity measures for the renal cohort.	24
Figure 10	Associations between normalized Shannon diversity and clinical variables in the bladder cohort.	25
Figure 11	Associations between normalized Shannon diversity and clinical variables in the renal cohort.	26
Figure 12	Survival analysis and Cox proportional hazards model for the bladder cohort.	27
Figure 13	Survival analysis and Cox proportional hazards model for the renal cohort.	28
Figure 14	Comparison of BCR repertoire features across healthy controls, renal cancer, and bladder cancer samples.	30
Figure 15	UMAP projections of IgH V gene usage in renal and bladder samples by age and health status.	31
Figure 16	Correlation between IgH V gene usage and clinical variables in the renal cancer cohort.	32
Figure 17	Correlation between IgH V gene usage and clinical variables in the bladder cancer cohort.	33
Figure 18	Appendix: Correlation between unique molecule counts (UMIs) and read counts across IgH clonotypes	54
Figure 19	Appendix: Comparison of BCR repertoire features across healthy controls, renal cancer, and bladder cancer samples split by chain (IgH, IgK, IgL) and combined.	55

Figure 20 Appendix: Correlation between IgH D and J gene usage
and clinical variables in the renal and bladder cancer co-
hort. 56

LIST OF TABLES

Table 1	Theoretical comparison between Shannon Diversity Index and Gini Index in immune repertoire analysis.	12
Table 2	Appendix: Overview of Columns for Bladder Dataset . . .	51
Table 3	Appendix: Overview of Columns for Renal Dataset	52
Table 4	Appendix: RStudio Version Information	53
Table 5	Appendix: R packages	53

ABBREVIATIONS

BCR	B-Cell Receptor
BH	Benjamini–Hochberg
BMI	Body Mass Index
CDR	Complementarity-Determining Region
CNV	Copy Number Variation
CRP	C-Reactive Protein
CSR	Class Switch Recombination
ctDNA	Circulating Tumor DNA
DNA	Deoxyribonucleic Acid
GC	Germinal Center
HR	Hazard Ratio
HPC	High Performance Computing
IgH	Immunoglobulin Heavy Chain
IgK	Immunoglobulin Kappa
IgL	Immunoglobulin Lambda
LDH	Lactate Dehydrogenase
NGS	Next-Generation Sequencing
ORF	Open Reading Frame
PCA	Principal Component Analysis
PCR	Polymerase Chain Reaction
QC	Quality Control
SHM	Somatic Hypermutation
TCR	T-Cell Receptor
TIL-Bs	Tumor-Infiltrating B Lymphocytes
TLS	Tertiary Lymphoid Structures
UMAP	Uniform Manifold Approximation and Projection
UMI	Unique Molecular Identifier